Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai Sells 40,000 Shares

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $1.93, for a total value of $77,200.00. Following the sale, the chairman now directly owns 1,331,543 shares in the company, valued at $2,569,877.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Neil Desai also recently made the following trade(s):

• On Monday, April 1st, Neil Desai sold 17,772 shares of Aadi Bioscience stock. The shares were sold at an average price of $2.31, for a total value of $41,053.32.
• On Monday, March 4th, Neil Desai sold 14,964 shares of Aadi Bioscience stock. The shares were sold at an average price of $2.10, for a total value of $31,424.40.
• On Friday, March 1st, Neil Desai sold 27,036 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.97, for a total value of $53,260.92.
• On Thursday, February 1st, Neil Desai sold 42,000 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.74, for a total value of $73,080.00.

Aadi Bioscience Stock Performance

AADI opened at $2.12 on Friday. The stock has a market cap of $52.05 million, a price-to-earnings ratio of -0.87 and a beta of 0.64. The stock’s 50 day moving average price is $2.06 and its 200-day moving average price is $2.77. Aadi Bioscience, Inc. has a one year low of $1.55 and a one year high of $8.60.

Aadi Bioscience (NASDAQ:AADI) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.07. Aadi Bioscience had a negative return on equity of 52.53% and a negative net margin of 270.04%. The company had revenue of $6.33 million for the quarter, compared to analysts’ expectations of $6.46 million. As a group, analysts predict that Aadi Bioscience, Inc. will post -2.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aadi Bioscience stock. Decheng Capital LLC acquired a new position in Aadi Bioscience, Inc. (NASDAQ:AADI) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 526,329 shares of the company’s stock, valued at approximately $1,063,000. Aadi Bioscience makes up about 0.3% of Decheng Capital LLC’s investment portfolio, making the stock its 22nd biggest holding. Decheng Capital LLC owned approximately 2.15% of Aadi Bioscience as of its most recent SEC filing. Institutional investors own 52.08% of the company’s stock.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.